|
Through Veritas Medicine's new ground-breaking
resource,
patients and physicians are matched against a current database of 1,200
government- and pharmaceutical-sponsored trials, and provided with
information
about only the most relevant treatment options. Each patient and caregiver
also has access to original and trusted corresponding information developed
by
Harvard- and Tufts-affiliated physicians, so they can make the most informed
choices about their treatment options.
Through Veritas Medicine's new resource, patients and physicians gain
relevant information based on personal needs and attributes, such as phase
of
disease, age, and gender, without revealing their identity.
Through Veritas Medicine's new resource, patients and physicians gain
relevant information based on personal needs and attributes, such as phase
of
disease, age, and gender, without revealing their identity. The resource is
also available to millions of additional users through leading
health-related
non-profit organizations and .coms, such as AEGIS, HIVandHepatitis.com,
Lifespire, MedicineNet.com, Your Doctor.com, HealthOnline, HepCBC-Hepatitis
C
Education and Prevention Society, and the Arthritis National Research
Foundation.
Seventy-five million people are diagnosed with chronic illnesses each
year
in the United States, but fewer than 5 percent participate in the thousands of
clinical trials and innovative treatments developed annually. Patients and
their caregivers have historically encountered difficulty in identifying,
gaining access to, and making sense of relevant clinical trials and
innovative
therapies. This has resulted from a lack of a centralized online resource
that provides comprehensive treatment options from both public and private
sectors — along with reliable corresponding information to help make sense
of
options. In addition to a dramatic impact on patients and their families,
the
lack of trial participation has severely impacted the entire health care
industry. For example, pharmaceutical companies, which have been reluctant to
post proprietary information online due to competitive concerns, typically
spend 40 weeks trying to find suitable patients, sacrificing more than
$1 million each day a new drug is delayed from the market.
"Veritas Medicine is transforming the clinical trials industry with the
launch of our new online resource, which enables patients and physicians to
identify highly relevant treatment options, and to make well-informed
choices
about those treatment options," said Joe Avellone, M.D., CEO of Veritas
Medicine.
Veritas Medicine is addressing security and confidentiality concerns
with
technology developed by the former co-lead of network security at M.I.T.
This
patent-pending security architecture enables patients and physicians to
receive information about relevant trials without revealing their identity.
The enhanced security features also appeal to pharmaceutical and
biotechnology
companies that have been reluctant to post proprietary information online
due
to competitive fears.
In addition to the initial challenge of identifying relevant trials,
patients and physicians have had difficulty in making sense of treatment
options due to outdated, confusing or unreliable corresponding information.
To address this, Veritas Medicine is working with respected
physician/scientists from Harvard- and Tufts-affiliated hospitals, each who
specializes in conditions currently featured by Veritas Medicine. These
physicians continually develop easy to understand analysis and information
about the latest breaking trials and treatments worldwide.
"There is significant confusion and frustration among patients and
physicians regarding the scope and relevance of new treatments for serious
illnesses," said Veritas Medicine's acting Chief Medical Officer William
Rodriguez, M.D., Harvard Medical School. "As an active researcher and a
practicing physician, I am thrilled to be working with Veritas Medicine to
provide accurate, understandable and current information about trials and
treatments to help patients and caregivers make informed choices about their
health care. Veritas Medicine is highly valuable for any patient diagnosed
with a life-altering illness."
Veritas Medicine is embarking on an aggressive strategy to bring its
powerful technology to millions worldwide. The company's partnerships with
information-rich health and medical resources such as Lifespire.com, a
leading
cancer resource, and the online publication HIVandHepatitis.com, enable
patients to access comprehensive trials information from other valuable Web
destinations.
"Lifespire is partnering with best-of-breed companies, such
as
Veritas Medicine, to create a complete resource that will serve the entire
cancer community," said Joelle Gropper Kaufman, president and CEO of
Lifespire. "By working in partnership with Veritas Medicine, we are giving
cancer patients and their physicians more options through Lifespire's
clinical
trials and interactive treatment and care services."
Ron Baker, editor in chief and publisher of HivandHepatitis.com said,
"Patients with HIV and hepatitis come to our site for practical, reliable
information about treatment options for their chronic conditions. Our quality online publication is pleased to partner with Veritas Medicine
to
offer our thousands of visitors access to innovative treatment and trials
opportunities."
Source: Veritas Medicine
CMLSupport Home Page This site was last updated on Nov. 18, 2000 Copyright © 2000 CMLSupport.com These contents may not be reproduced in whole or in part without the express written permission of the author, or she will beat you up and stuff. |